PALO ALTO, Calif.--Incyte Pharmaceuticals here, a leading genomic database company, has issued 1.2 million new shares of stock to finance the purchase of additional computer hardware, expansion of the company's facilities, and other capital requirements, as well as to pursue strategic investments. The stock sold for $67 per share.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.